A bacterium doesn't become resistant except through exposure to antibiotics the wrong way
A bacterium older than modern medicine is quietly outpacing the drugs designed to stop it. In January 2023, two Massachusetts residents became the first Americans confirmed to carry a gonorrhea strain already circulating in Asia and the United Kingdom — one that resists multiple antibiotics and bends, but has not yet broken, against the last reliable treatment. The discovery is less a crisis than a warning: that the slow, invisible erosion of antibiotic effectiveness, driven by misuse and silence, is a global condition no border can contain.
- A gonorrhea strain resistant to several antibiotics has crossed into the United States, with two unlinked Massachusetts cases suggesting the strain may already be circulating beyond what testing has captured.
- The bacteria's danger is amplified by invisibility — between 60 and 70 percent of infected women show no symptoms, creating a silent chain of transmission that gives the microorganism room to mutate and spread.
- Decades of improper antibiotic prescriptions — wrong drugs, wrong doses, wrong durations — have handed the bacteria the very conditions it needed to evolve, and health systems in many countries, including Brazil, have yet to correct course.
- Ceftriaxone still works, but it is the last reliable weapon; if resistance develops to it, medicine will have almost nowhere left to turn, making correct prescribing and expanded testing an urgent, not optional, priority.
- Public health authorities in the U.S. are alerting doctors and laboratories, urging higher testing rates and higher treatment doses, while Brazil — with half a million new gonorrhea cases annually and no routine screening — watches the global situation with acknowledged vulnerability.
On January 19, 2023, U.S. public health officials confirmed that two Massachusetts residents had tested positive for a gonorrhea strain already known in the United Kingdom and across Asia-Pacific — the first such cases on American soil. The strain, caused by Neisseria gonorrhoeae, shows reduced sensitivity to several antibiotics that doctors have long relied upon. Both patients responded to ceftriaxone, the current standard treatment, but the bacteria's diminishing susceptibility to other drugs has led American media to call it "supergonorrhea." The worry is not that treatment has collapsed — it's that medicine is losing options, one antibiotic at a time.
The World Health Organization has long identified the roots of this resistance: antibiotics prescribed without proper oversight, outdated medications still in use, and courses of treatment that are too short or too weak to fully eliminate the bacteria. As infectious disease specialist Rico Vasconcelos of the University of São Paulo explains, resistance doesn't emerge from nature's cruelty — it emerges from our own misuse of the tools we have.
The disease's silence makes the problem worse. Most infected women — between 60 and 70 percent — experience no symptoms at all, unknowingly carrying and transmitting the bacteria while it continues to evolve. Contact tracing could interrupt this cycle, but it remains rare. Brazil, which estimates 500,000 new gonorrhea cases each year, does not routinely screen for the infection; its public health focus falls on HIV and syphilis, leaving a hidden reservoir of gonorrhea largely undetected.
The two Massachusetts cases share no known connection, which suggests the strain is already moving through the population. U.S. authorities have alerted clinicians and labs, recommending higher testing rates and increased ceftriaxone doses. Brazil has not yet detected the resistant strain, but Vasconcelos is candid about the risk — and about his country's response: "Unfortunately, here in Brazil we are doing everything wrong." The path forward is not abstinence, but accuracy: find infections early, treat them correctly, and follow where they've been.
Two people in Massachusetts tested positive for a strain of gonorrhea that shrugs off multiple antibiotics, the U.S. Department of Public Health announced on January 19th. These are the first confirmed cases in America, though the strain has already surfaced in the United Kingdom and across Asia-Pacific. Public health officials are calling it a serious problem.
The bacterium behind gonorrhea, Neisseria gonorrhoeae, ranks as the second most common bacterial sexually transmitted infection worldwide. Brazil alone sees roughly 500,000 new cases each year. What makes this particular strain noteworthy is its reduced sensitivity to the drugs doctors have relied on for decades. The two Massachusetts patients did respond to ceftriaxone, the current standard treatment, but their infections showed diminished susceptibility to several other antibiotics—a gap that prompted American media outlets to dub it "supergonorrhea." The concern is not that treatment has failed entirely, but that the bacteria is losing ground to one more weapon in medicine's arsenal. If ceftriaxone stops working, doctors will have fewer options.
The World Health Organization points to several drivers of this resistance. Antibiotics are sometimes available without proper oversight. Doctors in various parts of the world, including Brazil, still prescribe outdated medications that no longer work effectively. When a bacterium encounters the wrong drug at the wrong dose for the wrong duration, it gets an opportunity to select for resistant strains. That's not a failure of nature—it's a consequence of how we use the tools we have. Rico Vasconcelos, an infectious disease specialist at the University of São Paulo's medical school, puts it plainly: "A bacterium doesn't become resistant to an antibiotic except through exposure to an antibiotic in the wrong dose, for the wrong time, in the wrong way."
Another factor accelerates resistance: the disease often produces no symptoms, especially in women. Between 60 and 70 percent of infected women show nothing at all. They carry the bacteria, pass it along unknowingly, and give the microorganism room to mutate. Contact tracing—finding and testing the sexual partners of infected people—could interrupt this cycle, but it's not standard practice in most countries. Brazil, for instance, does not routinely screen for gonorrhea or chlamydia among sexually active people. When screening happens, it focuses on HIV and syphilis. The result is a hidden reservoir of infection.
The two Massachusetts cases have no known connection to each other, which suggests the strain is circulating. Epidemiologists are now hunting for other people who may have acquired it. The U.S. has issued alerts to doctors and laboratories, urging higher testing rates among symptomatic patients and higher doses of ceftriaxone for treatment. Margret Cooke, the state's public health commissioner, called on all sexually active people to get tested regularly, consider reducing their number of partners, and use condoms consistently.
Brazil has not yet detected this resistant strain, but the risk is real. Vasconcelos notes that the world saw how quickly COVID-19 and monkeypox spread in 2022. "Risk always exists because there is a very large flow of people in the world," he says. The Brazilian Ministry of Health recommends that anyone with symptoms seek care through the public health system, where treatment is free and should extend to sexual partners as well.
The path forward depends on two things: doctors prescribing antibiotics correctly—the right drug, the right dose, the right duration—and health systems actually testing people who might be infected. Without contact tracing and proper screening, asymptomatic carriers will continue spreading the bacteria, giving it more chances to evolve. Vasconcelos is blunt about Brazil's current approach: "Unfortunately, here in Brazil we are doing everything wrong." The solution isn't to ask people to stop having sex. It's to find infections before they spread, treat them right, and track where they've been.
Citações Notáveis
A bacterium doesn't become resistant to an antibiotic except through exposure to an antibiotic in the wrong dose, for the wrong time, in the wrong way.— Rico Vasconcelos, infectious disease specialist, University of São Paulo
Unfortunately, here in Brazil we are doing everything wrong, because there is no screening for sexually transmitted infections among sexually active people.— Rico Vasconcelos
A Conversa do Hearth Outra perspectiva sobre a história
Why is this strain showing up now, in Massachusetts specifically?
It's not new—it was identified in Asia in 2021 and 2022, and it's been in the UK. This is the first time it's reached the U.S. or the Americas. It's a sign the strain is moving around the world, probably through travel and sexual contact.
The patients recovered, though. So why the alarm?
They recovered because ceftriaxone still works. But the strain showed reduced sensitivity to multiple other antibiotics. If it loses sensitivity to ceftriaxone too, we lose another tool. We have other options, but each one we lose matters.
How does a bacterium become resistant in the first place?
Exposure to antibiotics at the wrong dose, for the wrong duration, in the wrong way. When doctors prescribe outdated drugs or patients don't finish their course, the bacteria that survive are the ones that can handle the drug. Those resistant strains multiply.
Is Brazil at risk?
Not yet—there are no super-resistant cases there. But Brazil has 500,000 new gonorrhea cases a year, and the health system doesn't routinely test for it. That means asymptomatic carriers are spreading it without knowing, giving the bacteria more chances to mutate.
What would actually stop this?
Two things: doctors prescribing antibiotics correctly, and health systems testing people who might be infected. Contact tracing matters too. If you find infections early and treat them right, you interrupt transmission. Without that, the bacteria just keeps circulating and evolving.
So the real problem isn't the bacteria. It's us.
Exactly. The bacterium is doing what bacteria do. We're the ones making mistakes—wrong prescriptions, no screening, no follow-up with partners. That's what's driving resistance.